Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder

AI Summary

Researchers from DZNE, the Hertie Institute for Clinical Brain Research, and partner institutions have tested an experimental approach for spinocerebellar ataxia type 3 in cultured human neurons. The treatment selectively reduced a harmful protein in lab models, offering a potential research avenue for this rare inherited neurodegenerative disease.

Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal, have developed and successfully tested in human neurons cultured in the lab a new approach for treating the rare neurodegenerative disease spinocerebellar ataxia type 3 (SCA3).